Clinical Trial

A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a clinical study to explore the efficacy and safety of BL-B01D1+PD-1/PD-L1 monoclonal antibody in patients with advanced biliary tract cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-11.
Status change: Not Yet Recruiting → Recruiting 2025-07-01
Trial Details
NCT Number NCT06978114
Lead Sponsor Sichuan Baili Pharmaceutical Co., Ltd.
Collaborators: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Conditions Advanced Biliary Tract Cancer
Enrollment 46 participants
Start Date 2025-06-10
Primary Completion 2027-05 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-07-02